/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Akebia Therapeutics Inc Share Price Today: Live Updates & Key Insights

Akebia Therapeutics Inc share price today is $1.22, up 0%. The stock opened at $1.22 against the previous close of $1.22, with an intraday high of $1.235 and low of $1.2.

Akebia Therapeutics Inc Share Price Chart

style
pb-0

Akebia Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Akebia Therapeutics Inc Share Price Performance

$1.22 0(0%) AKBA at 27 Jul 2026 01:54 PM Drug Manufacturers - Specialty & Generic
Lowest Today 1.2
Highest Today 1.235
Today’s Open 1.22
Prev. Close 1.22
52 Week High 3.81
52 Week Low 0.82
Day’s Range: Low 1.2 High 1.235
52-Week Range: Low 0.82 High 3.81
1 day return -
1 Week return -4.66
1 month return +7.92
3 month return -14.03
6 month return -14.63
1 year return -65.97
3 year return -14.93
5 year return -50.2
10 year return -

Akebia Therapeutics Inc Institutional Holdings

BlackRock Inc 6.97

Vanguard Group Inc 5.97

State Street Corp 4.33

Vanguard Capital Management, LLC 4.16

Vanguard Total Stock Mkt Idx Inv 2.95

iShares Russell 2000 ETF 2.55

Geode Capital Management, LLC 2.41

The Goldman Sachs Group Inc 1.34

Vanguard Institutional Extnd Mkt Idx Tr 1.18

Citigroup Inc 1.06

Bank of America Corp 1.03

Fidelity Small Cap Index 0.93

Qube Research & Technologies 0.89

Millennium Management LLC 0.89

Vanguard Portfolio Management, LLC 0.83

iShares Russell 2000 Growth ETF 0.81

Charles Schwab Investment Management Inc 0.75

Nantahala Capital Management, LLC 0.75

Foord Global Equity (Lux) A 0.73

Northern Trust Corp 0.73

Renaissance Technologies Corp 0.68

Foord Global Equity Class B 0.68

AQR Capital Management LLC 0.67

Vanguard Fiduciary Trust Co 0.66

Fidelity Enhanced Small Cap Core ETF 0.61

Russell 2000 Equity Index Fund B 0.59

Russell 2000 Index Non-Lendable Fund 0.59

Vanguard Russell 2000 ETF 0.55

State St Russell Sm/Mid Cp® Indx SL Cl I 0.54

Jane Street Group LLC 0.54

Fidelity Extended Market Index 0.52

Citadel Advisors Llc 0.52

Acadian Asset Management LLC 0.51

Schwab US Small-Cap ETF™ 0.47

State St Russell Sm Cap® Idx SL Cl I 0.34

iShares Micro-Cap ETF 0.32

Vanguard Health Care ETF 0.28

Extended Equity Market Fund B 0.26

Extended Equity Market Fund E 0.26

Blackrock Extended Mkt Fund CF 0.26

Akebia Therapeutics Inc Market Status

Strong Buy: 3

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Akebia Therapeutics Inc Fundamentals

Market Cap 327.28 M

PB Ratio 12.4452

PE Ratio 0.0

Enterprise Value 226.38 M

Total Assets 376.57 M

Volume 1496092

Akebia Therapeutics Inc Company Financials

Annual Revenue FY23:194327000 194.3M, FY22:292602000 292.6M, FY21:213578000 213.6M, FY20:295307000 295.3M, FY19:335001000 335.0M

Annual Profit FY23:143044000 143.0M, FY22:207806000 207.8M, FY21:60184000 60.2M, FY20:-601000 -0.6M, FY19:189665000 189.7M

Annual Net worth FY23:-56946000 -56.9M, FY22:-106009000 -106.0M, FY21:-244870000 -244.9M, FY20:-349867000 -349.9M, FY19:-279659000 -279.7M

Quarterly Revenue Q1/2026:53544000 53.5M, Q3/2025:58766000 58.8M, Q2/2025:62472000 62.5M, Q1/2025:57336000 57.3M, Q3/2024:37428000 37.4M

Quarterly Profit Q1/2026:40926000 40.9M, Q3/2025:49065000 49.1M, Q2/2025:52553000 52.6M, Q1/2025:49711000 49.7M, Q3/2024:23267000 23.3M

Quarterly Net worth Q1/2026:-9054000 -9.1M, Q3/2025:540000 0.5M, Q2/2025:247000 0.2M, Q1/2025:6112000 6.1M, Q3/2024:-20039000 -20.0M

About Akebia Therapeutics Inc & investment objective

Company Information Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Organisation Drug Manufacturers - Specialty & Generic

Employees 194

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. John P. Butler MBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow

Akebia Therapeutics Inc FAQs

What is the share price of Akebia Therapeutics Inc today?

The current share price of Akebia Therapeutics Inc is $1.22.

Can I buy Akebia Therapeutics Inc shares in India?

Yes, Indian investors can buy Akebia Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Akebia Therapeutics Inc shares in India?

You can easily invest in Akebia Therapeutics Inc shares from India by:

Can I buy fractional shares of Akebia Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Akebia Therapeutics Inc?

Akebia Therapeutics Inc has a market cap of $327.28 M.

In which sector does Akebia Therapeutics Inc belong?

Akebia Therapeutics Inc operates in the Drug Manufacturers - Specialty & Generic sector.

What documents are required to invest in Akebia Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Akebia Therapeutics Inc?

The PE ratio of Akebia Therapeutics Inc is N/A and the PB ratio is 12.45.